5.6.2026 – UMBI Research Updates Series (RUS) in Molecular Medicine

 

5 June 2026 | This morning’s ๐”๐Œ๐๐ˆ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐”๐ฉ๐๐š๐ญ๐ž ๐’๐ž๐ซ๐ข๐ž๐ฌ ๐ข๐ง ๐Œ๐จ๐ฅ๐ž๐œ๐ฎ๐ฅ๐š๐ซ ๐Œ๐ž๐๐ข๐œ๐ข๐ง๐ž ๐๐จ. ๐Ÿ๐Ÿ’/๐Ÿ๐ŸŽ๐Ÿ๐Ÿ” featured an insightful presentation by ๐”๐Œ๐๐ˆ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐…๐ž๐ฅ๐ฅ๐จ๐ฐ, ๐ƒ๐ซ. ๐’๐ข๐ญ๐ข ๐€๐ข๐ฌ๐ก๐š๐ก ๐’๐ฎ๐ฅ๐š๐ข๐ฆ๐š๐ง, entitled โ€œFatty Liver: Thin Doesn’t Mean Immuneโ€.

The session highlighted fatty liver disease as a growing global health concern and a silent epidemic, with prevalence continuing to rise worldwide. Dr. Aishah shared that the global prevalence reached approximately 38% in 2022, affecting an estimated 3 billion individuals, while more than 30% of the population in South-East Asia is affected. In Malaysia, findings from the ๐๐š๐ญ๐ข๐จ๐ง๐š๐ฅ ๐‡๐ž๐š๐ฅ๐ญ๐ก ๐š๐ง๐ ๐Œ๐จ๐ซ๐›๐ข๐๐ข๐ญ๐ฒ ๐’๐ฎ๐ซ๐ฏ๐ž๐ฒ (๐๐‡๐Œ๐’) ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ‘ indicate that approximately 28% of Malaysians have fatty liver disease.
A key focus of the presentation was the often-overlooked phenomenon of Lean MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), where ๐ข๐ง๐๐ข๐ฏ๐ข๐๐ฎ๐š๐ฅ๐ฌ ๐ฐ๐ข๐ญ๐ก ๐š ๐ง๐จ๐ซ๐ฆ๐š๐ฅ ๐›๐จ๐๐ฒ ๐ฆ๐š๐ฌ๐ฌ ๐ข๐ง๐๐ž๐ฑ (๐๐Œ๐ˆ) ๐ฆ๐š๐ฒ ๐ฌ๐ญ๐ข๐ฅ๐ฅ ๐๐ž๐ฏ๐ž๐ฅ๐จ๐ฉ ๐Ÿ๐š๐ญ๐ญ๐ฒ ๐ฅ๐ข๐ฏ๐ž๐ซ. The audience was introduced to the concept of ๐“๐Ž๐…๐ˆ (๐“๐ก๐ข๐ง ๐Ž๐ฎ๐ญ๐ฌ๐ข๐๐ž, ๐…๐š๐ญ ๐ˆ๐ง๐ฌ๐ข๐๐ž), describing individuals with relatively low subcutaneous fat but high levels of visceral fat, which may increase MASLD risk despite appearing lean. Dr. Aishah also discussed the ๐ฉ๐จ๐ญ๐ž๐ง๐ญ๐ข๐š๐ฅ ๐ซ๐จ๐ฅ๐ž ๐จ๐Ÿ ๐ญ๐ก๐ž ๐๐๐๐‹๐€๐Ÿ‘๐ˆ๐Ÿ๐Ÿ’๐Ÿ–๐Œ ๐ ๐ž๐ง๐ž๐ญ๐ข๐œ ๐ฏ๐š๐ซ๐ข๐š๐ง๐ญ ๐ข๐ง ๐‹๐ž๐š๐ง ๐Œ๐€๐’๐‹๐ƒ ๐ฌ๐ฎ๐ฌ๐œ๐ž๐ฉ๐ญ๐ข๐›๐ข๐ฅ๐ข๐ญ๐ฒ.

The presentation further explored the differences between obese and lean MASLD profiles, highlighting current clinical challenges and the tendency for ๐‹๐ž๐š๐ง ๐Œ๐€๐’๐‹๐ƒ ๐ฉ๐š๐ญ๐ข๐ž๐ง๐ญ๐ฌ ๐ญ๐จ ๐›๐ž ๐ฎ๐ง๐๐ž๐ซ-๐ฌ๐œ๐ซ๐ž๐ž๐ง๐ž๐ ๐๐ฎ๐ž ๐ญ๐จ ๐ฉ๐ซ๐ž๐ฏ๐š๐ข๐ฅ๐ข๐ง๐  ๐œ๐ฅ๐ข๐ง๐ข๐œ๐š๐ฅ ๐›๐ข๐š๐ฌ ๐ญ๐ก๐š๐ญ ๐š๐ฌ๐ฌ๐จ๐œ๐ข๐š๐ญ๐ž๐ฌ ๐Ÿ๐š๐ญ๐ญ๐ฒ ๐ฅ๐ข๐ฏ๐ž๐ซ ๐ฉ๐ซ๐ข๐ฆ๐š๐ซ๐ข๐ฅ๐ฒ ๐ฐ๐ข๐ญ๐ก ๐จ๐›๐ž๐ฌ๐ข๐ญ๐ฒ.

The session concluded with an engaging Q&A discussion, reflecting strong interest from participants. Appreciation is extended to Dr. Aishah for her informative sharing and to all attendees for their active participation and insightful questions.



SDG 4 – Quality Education